Artemisinin Conference 2010

12-14 October 2010
Antananarivo, Madagascar

ARTEMISININ CONFERENCE FINAL REPORT [DOC: 430Kb]

The Artemisinin Conference 2010 was jointly organized by WHO, RBM, MMV, and supported by DFID, UK. All conference presentations are available below.

The main objectives of the conference were to:

  • Present ACT demand forecasts for 2011-2012 and latest ACT demand forecasting mechanisms, including impact of vector control and latest malaria diagnostics
  • Identify actual 2010 artemisinin production, future demand, prices and production costs
  • Review A2S2 and future support needs to ensure consistent artemisinin production
  • Update on latest developments in high yielding, Artemisia variety development
  • Present new technology to improve artemisinin processing efficiencies and APIs
  • Discuss latest developments in analytical techniques for Artemisia and artemisinin
  • Identify progress on ensuring artemisinin as a starting material and discuss artemisinin quality needs
  • Present latest developments in semi-synthetic artemisinin and fully synthetic treatments
  • Present and discuss reports regarding artemisinin resistance

View the conference agenda. [PDF: 63Kb]

 


Conference Presentations:

Tuesday 12 October 2010

09.00 – 09.10

Opening remarks, objectives and Priority Actions [PDF: 17Kb] from the 2009 Mumbai conference - Malcolm Cutler, Andrea Bosman, Jan Van Erps

09:20 – 10.00

Keynote address:

  1. History of Malaria Treatment in Madagascar [PDF: 1.25Mb] - Milijaona Randrianarivelojosia, Institute Pasteur de Madagascar   
  2. Lessons learnt from ACT use in Madagascar [PDF: 946Kb] - Benjamin Ramarosandratana, National Malaria Control Programme

10.30 – 11.15

New Developments in High Yielding Artemisia Varieties and Production Methods

  1. Implications of Intensification of Artemisia Production [PDF: 2Mb] -  Antony Ellman, NRI (Read Antony Ellman's article: Cultivation of Artemisia Annua in Africa and Asia)
  2. Comparison of Different Drying Techniques in Madagascar [PDF: 587Kb] - Xavier Simonnet, Mediplant
  3. CNAP High Yielding Varieties – Progress Update [PDF: 2.78Mb] - Dianna Bowles, CNAP, York, UK 
  4. NIAB, UK – High Yielding Artemisia Development [PDF: 1.4Mb] - Steve Bentley, NIAB, UK

11.1512.30

Results of New Purification Technology on Increasing Production Efficiency and Reducing Costs

  1. New Purification Technology to Increase Efficiency and Reduce Costs [PDF: 1.29Mb] - Colin Hill, ETDL, UK and Bhupinder Khambay, Kamtech Tech, UK

12.30 – 13.15

Latest Developments in Analytical Techniques for Leaf Analysis, In-Process Assays and Artemisinin

  1. Challenges in Artemisinin Analysis [PDF: 223Kb] - Bhupinder Khambay – Kamtech Tech. UK
  2. Determination of Artemisinin & Moisture Content of Leaves using Near Infrared Spectroscopy (NIRS)  [PDF: 799Kb] - Xavier Simonnet – Mediplant
  3. Anti-Malarial Drug Testing: Tests, Reference Standards & Assays [PDF: 4.29Mb] – SensaPharm, UK

14.15 – 15.15

ACT Market – Latest Forecasts and Demand Forecasting Methods

  1. ACT Forecasts for 2010-11 [PDF: 88Kb] – MIT, Zaragosa presented by Henk den Besten
  2. Global ACT Demand Forecast [PDF: 60Kb]– Jeffrey Chung, CHAI
  3. Consolidated ACT Demand Forecast Programme [PDF: 179Kb] – Mathieu Lamiaux, BCG

Implications of Vector Control and RDTs on ACT Forecasts

  1. Impact of Vector Control and Malaria Diagnostics on ACT Consumption [PDF: 5.01Mb]  - Andrea Bosman, Global Malaria Programme, WHO

15.1516.00 

Global Fund and other Public Sector ACT Supply Mechanisms

  1. Challenges in Procurement of Artemisinin Based Medicines [PDF: 228Kb] – Fabienne Jouberton, Global Fund
  2. ACTs in the Public Sector [PDF: 135Kb] – Donald Dickerson, Presidents Malaria Initiative
  3. UNICEF Update on ACT Procurement [PDF: 719Kb] – Jon Blasco, UNICEF
  4. UNITAID Support for Malaria Prevention and Control [PDF: 800Kb] – Yohannes Ambachew, UNITAID

16.20 – 17.00

AMFm – Update on Implementation and Implications for Manufacturers

  1. AMFm Update [PDF: 292Kb] – Fabienne Jouberton

17.0018.00

Artemisinin/API Forecasts to meet ACT Demand.  Pricing and Manufacturing Cost Implications

  1. Artemisinin Market, Quantities & Pricing [PDF: 153Kb]  - Jacques Pilloy, Artepal

 


 

Wednesday 13 October 2010

09.00 – 10.00

Assured Artemisinin Supply System (A2S2) – Activity Update, Review of Support Mechanisms and Future Needs

  1. A2S2 - Progress & Status [PDF: 132Kb] – Henk den Besten, i+solutions & Koert Jansen, Triodos Bank

10.00 – 10.30

Recent Findings on Artemisinin Tolerance/Resistance

  1. Update on Tolerance/Resistance and Therapeutic Efficacy of Artemisinin in SE Asia [PDF: 5.07Mb] - Pascal Ringwald, WHO (presented by Andrea Bosman)

10.30 – 11.00

Threat of Substandard ACTs and Oral-Based Monotherapies

  1. Quality of Antimalarial Medicines in Sub Saharan Africa [PDF: 202Kb] - Jitka Sabartova and Andrea Bosman, WHO
  2. Threat of Oral Artemisinin-Based Monotherapies [PDF: 2.96Mb] – Andrea Bosman, WHO

11.20 – 12.10

New API Developments

  1. Artemisinins, the Marvellous Peroxidic Antimalarials [PDF: 4.71Mb] - Dr Richard Haynes – Hong Kong University of Science & Technology

12.10 – 13.00

Discussion regarding clarification regarding Artemisinin as a Starting Material and Artemisinin Quality Standards

  1. Update on Defining Artemisinin as a Starting Material [PDF: 361Kb] - Valérie Faillat-Proux, Rapporteur of Staring Material Working Group
  2. Artemisinin as a Starting Material [PDF: 1.03Mb] - Walter Cabri – Sigma-Tau

14.00 – 15.00

Artemisinin, API and ACT Production:  Industry Perspectives on Present and Future Production Needs, Opportunities and Threats

  1. Artemisinin Cultivation in China, 2010-2011 [PDF: 4.76Mb] – Christine Lin, Pidi Standard Ltd
  2. Guilin Pharma, China [PDF: 2.12Mb] – Vincernt Jin
  3. Artemisinin Production in Vietnam, 2010 [PDF: 120Kb] – Huy Nguyen Hiey
  4. CIPLA [PDF: 322Kb] – India Industry Perspective – Prashant Sisodia

 


 

Thursday 14 October 2010

9.00 – 11.00

Review of Latest Developments of Semi Synthetic Artemisinin Technologies 

  1. Semi-Synthetic Project One World Health [PDF: 517Kb] – Tue Nguyen
  2. Semi-Synthetic Artemisinin Project [PDF: 4.25Mb] – Henri Farret, Sanofi-aventis

Bionexx Madagascar – Historical & Future Perspectives for Artemisinin Production

  1. Bionexx, Historical and Future Perspectives [PDF: 6.51Mb] - Charles Giblain, Bionexx, Madagascar

Recommendations to Improve ACT Tender Procedures

  1. Mission Malaria and Tender Procedure Recommendations [PDF: 575Kb] - Murali Sarma, IPCA

Cellphone Technology for Stock Management

  1. SMS for Life [PDF: 1.57Mb] - Jan Van Erps, RBM Partnership

Presentations of conclusions and recommendations by Break Out Sessions

11.30 – 12.15

  1. Artemisia, Artemisinin - Technical Issues & Developments Session Overview [PDF: 89.4Kb] - Rapporteurs  – Charles Giblain, Antony Ellman

12.15 – 13.30

  1. ACT/API/Artemisinin Forecast and Supply, A2S2, Monotherapies and Substandard Treatments Session Overview [PDF: 34.8Kb] - Rapporteurs -  Andrea Bosman, Jan Van Erps

16:30 -17.30

Presentation of key findings of the conference [PDF: 153Kb] - Antony Ellman & Malcolm Cutler

 


 

Please contact us if you have any questions about this event.